Kangzhi Pharmaceutical released its 2026 interim report on August 26. First-half operating revenue was 145 million yuan, down 37.7 percent year on year. Net loss attributable to the parent was 32.77 million yuan, narrowing from a loss of 54.08 million yuan in the same period last year. Net loss attributable to the parent after deducting non-recurring items was 41.43 million yuan, down from a loss of 56.01 million yuan a year earlier. Net operating cash flow was negative 11.24 million yuan, down 116.9 percent year on year. Earnings per share were negative 0.072 yuan. In the second quarter, operating revenue was 48.31 million yuan, down 59.7 percent year on year, and net loss attributable to the parent was 21.02 million yuan, narrowing from a loss of 44.39 million yuan in the same period last year. As of the end of the second quarter, total assets were 1.712 billion yuan, down 4.4 percent from the end of the previous year, and net assets attributable to the parent were 867 million yuan, down 3.6 percent from the end of the previous year. The company said its operating business did not change significantly during the reporting period, remaining focused on children's medicines and maternal and infant health products, while adjusting its product mix, reducing cooperation on agency products, and expanding sales of its own products.
Hainan Honz Pharmaceutical CoRevenue down 37.7%, loss narrowed but still negative, cash flow worsened.
